The family of Na+/H+ exchangers, also known as sodium/hydrogen exchangers or NHEs, converts Na+ into H+ in response to concentration gradients, helping to maintain the stability of cytoplasmic pH and cell volume.
There are nine different NHE isoforms in humans, some of which are found on intracellular organelles and function primarily on the plasma membrane. Nearly every tissue's plasma membrane expresses NHE1, which is crucial for cardiac health. While NHE3 predominates in the GI tract and kidneys, NHE2 is expressed in the GI tract and helps to maintain the stomach's pH and homeostasis. The brain and stomach both contain large amounts of NHE4 and NHE5, respectively. Many organ system membranes express NHE6–9 in intracellular compartments, but NHE8 is an exception and is expressed apically.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4716 | BI-9627 | 1204329-34-9 | BI-9627 is a novel and highly potent NHE1 (sodium-hydrogen exchanger isoform 1) inhibitor with with anEC50of 31 nM. |
|
V74207 | NHE3-IN-2 | 92434-13-4 | NHE3-IN-2 is a Na+/H+ exchanger 3 (NHE3) inhibitor (For more details, check and find patent WO2001079186A1 6-Chlor-4-phenyl-2-chinazolinyl-guanidin). |
|
V4284 | Tenapanor | 1234423-95-0 | Tenapanor (formerly RDX-5791; RDX 5791;AZD-1722;AZD1722; trade name Ibsrela) is afirst-in-class inhibitor of sodium-hydrogen exchanger (NHE3) approved by FDA in 2019 for the treatment of irritable bowel syndrome with constipation (IBS-C). |
|
V4283 | Tenapanor HCl | 1234365-97-9 | Tenapanor 2HCl (formerly AZD-1722;AZD1722;RDX-5791; RDX 5791; Ibsrela), thedihydrochloride salt ofTenapanor, is a novel and potent inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3 approved in 2019 for the treatment of irritable bowel syndrome with constipation (IBS-C). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
